Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Salvatore Finazzo

Obstetrics Trenton, MI Doctor of Osteopathy

NPI 1033180161 CMS profile 319522

1651 Kingsway Ct, Ste. A, Trenton, MI 48183

Open in the dashboard

General payments

$13,403

296 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Salvatore Finazzo of Trenton, MI is reported in the CMS Open Payments database as having received $13,403 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Obstetrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,320 38
2024 General $1,032 47
2023 General $2,767 45
2022 General $4,120 48
2021 General $839 53
2020 General $449 27
2019 General $1,877 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Salvatore Finazzo
  • Obstetrics median
  • Middle half of Obstetrics
  • National median

In program year 2025, general payments to Salvatore Finazzo were reported at $2,320. Among 649 Obstetrics profiles paid that year, the median was $181 and the middle half received between $61 and $424.

Show as a table
Year Salvatore Finazzo Obstetrics median Middle half National median
2019 $1,877 $177 $60–$381 $163
2020 $449 $92 $35–$201 $114
2021 $839 $125 $40–$351 $132
2022 $4,120 $186 $65–$448 $149
2023 $2,767 $183 $61–$451 $160
2024 $1,032 $176 $62–$406 $164
2025 $2,320 $181 $61–$424 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $6,708 20 payments
  2. Merck Sharp & Dohme Corporation $1,518 8 payments
  3. AbbVie, Inc. $762 32 payments
  4. Sumitomo Pharma America, Inc. $593 29 payments
  5. Astellas Pharma US Inc $536 20 payments
  6. Hologic, LLC $308 16 payments
  7. Myovant Sciences Inc. $306 12 payments
  8. Sage Therapeutics, Inc. $272 12 payments
  9. Avion Pharmaceuticals $227 24 payments
  10. Pfizer Inc. $221 15 payments
  11. Other $1,952 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $6,396 4 payments
  2. Food and Beverage $5,305 283 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,375 1 payment
  4. Education $328 8 payments
Products named General payments · program years 2019–2025
  1. NEXPLANON Etonogestrel $6,658 18 payments
  2. NEXPLANON Womens Health $1,375 1 payment
  3. MYFEMBREE $756 35 payments
  4. ORILISSA $428 17 payments
  5. LO LOESTRIN FE $384 16 payments
  6. ORIAHNN $310 11 payments
  7. Veozah $273 16 payments
  8. ZURZUVAE $272 12 payments
  9. Balcoltra $214 23 payments
  10. PREMARIN $202 14 payments
  11. Other $3,637 201 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

140

Median for Obstetrics & Gynecology: 65

Drug cost

$10,204

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

11.4%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 16 $6,306
Estradiol Generic 69 $2,985
Raloxifene Hcl Generic 14 $759
Zolpidem Tartrate Generic 14 $112
Fluconazole Generic 15 $23
Letrozole Generic 12 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$16,844

Medicare's payments for the services billed

Medicare patients

77

Average age 67

Services billed

165

77 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 39%
Depression 27%
Osteoporosis 25%
Ischemic heart disease 23%
Diabetes 22%
Chronic kidney disease 22%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $177
  • PFIZER INC. $7
$184 — —
Veozah
  • Astellas Pharma US Inc $111
$111 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $51
$51 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $15
$15 — —
GARDASIL
  • Merck Sharp & Dohme Corporation $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record